卡维地洛治疗慢性心力衰竭短期疗效及对血浆N-端脑钠素前体的影响  

The short effects of carvedilol in the therapy of chronic heart failure and changes of plasma level of N-terminal pro-brain natriuretic peptide

作　　者：赵士超[1] 曹林生[1] 

机构地区：[1]华中科技大学协和医院心内科华中科技大学同济医学院心血管病研究所

出　　处：《临床心血管病杂志》2006年第11期689-691,共3页Journal of Clinical Cardiology

摘　　要：目的:探讨卡维地洛治疗慢性心力衰竭短期疗效及对血浆N-端脑钠素前体(Nt-proBNP)的影响。方法:采用随机对照研究,将92例慢性心力衰竭患者随机分成卡维地洛组和对照组,2组疗程均为8周,2组患者均于给药前及给药后8周,观察临床疗效,超声心动图测定左心室射血分数(LVEF)、心排血量(CO)及心排指数(CI),用电化学发光免疫学方法及夹心法原理检测血浆Nt-proBNP浓度。结果:与给药前相比,对照组LVEF、CO和CI无显著变化,而卡维地洛组LVEF、CO和CI增加(P<0.05)。2组Nt-proBNP血浆浓度明显降低,但卡维地洛组与对照组比Nt-proBNP血浆浓度下降更明显(P<0.05)。结论:卡维地洛能够在短期改善心功能不全。而Nt-proBNP血浆浓度是一个反映心力衰竭严重程度、判断疗效的敏感指标,值得临床推广和应用。Objective：The present study evaluated the consequences by Carvedilol treatment on chronic heart failure（CHF） and changes of plasma level of N-terminal pro-brain natriuretic peptide （NT-proBNP）. Method.. 92 patients with CHF were randomly divided into Carvedilol-treated group and control-treated group according to the random control study. Both of the groups were treated for 8 weeks and the clinical effects were observed before and after 8-week-administration. The LVEF,CO and CI were evaluated and plasma level of NT-proBNP were examined by electrochemiluminescene immunoassay based on a sandwich format with unextracted EDTA plasma. Result： The LVEF ,CO and CI were not improved in the control-treated group, the LVEF,CO and CI were significantly improved in Carvedilol-treated group（ P〈0.05）. After 8 weeks , the plasma level of NT-proBNP were significantly lower than before treatment in both groups; the plasma level of NT-proBNP in Carvedilol-treating group were significantly lower than those of the control group （ P 〈0.05） . Conclusion：Carvedilol a beta-blocker with vasodilator properties treats patients with CHF in many mechanisms. It can improve LVEF ,CO and CI in short time. The plasma level of Nt-proBNP is a sensitive marker, judging the severity of heart failure and prognosis, which deserves to be utilized broadly.

关 键 词：卡维地洛 慢性心力衰竭 N-端脑钠素前体 

分 类 号：R972[医药卫生—药品]